Gupta Sagar, Sgourakis Nikolaos G
bioRxiv. 2024 Jun 6:2024.06.04.597418. doi: 10.1101/2024.06.04.597418.
Peptides presented by class I major histocompatibility complex (MHC-I) proteins provide biomarkers for therapeutic targeting using T cell receptors (TCRs), TCR-mimicking antibodies (TMAs), or other engineered protein binders. Despite the extreme sequence diversity of the Human Leucocyte Antigen (HLA, the human MHC), a given TCR or TMA is restricted to recognize epitopic peptides in the context of a limited set of different HLA allotypes. Here, guided by our analysis of 96 TCR:pHLA complex structures in the Protein Data Bank (PDB), we identify TCR contact residues and classify 148 common HLA allotypes into T-cell cross-reactivity groups (T-CREGs) on the basis of their interaction surface features. Insights from our work have actionable value for resolving MHC-I restriction of TCRs, guiding therapeutic expansion of existing therapies, and informing the selection of peptide targets for forthcoming immunotherapy modalities.
由I类主要组织相容性复合体(MHC-I)蛋白呈递的肽为使用T细胞受体(TCR)、TCR模拟抗体(TMA)或其他工程化蛋白结合物进行治疗靶向提供了生物标志物。尽管人类白细胞抗原(HLA,即人类MHC)具有极端的序列多样性,但给定的TCR或TMA仅限于在有限的一组不同HLA同种异型的背景下识别表位肽。在此,在我们对蛋白质数据库(PDB)中96个TCR:pHLA复合体结构的分析指导下,我们确定了TCR接触残基,并根据其相互作用表面特征将148种常见HLA同种异型分类为T细胞交叉反应性组(T-CREGs)。我们工作的见解对于解决TCR的MHC-I限制、指导现有疗法的治疗性扩展以及为即将到来的免疫治疗模式选择肽靶点具有可操作的价值。